Medivir to present at the Redeye Life Science Day
Get Alerts IGMS Hot Sheet
Join SI Premium – FREE
CEO
The In Focus interview is live broadcasted and can be followed at the event page;
https://www.redeye.se/events/915984/redeye-life-science-day-2023
For additional information, please contact
Telephone: +46 8 5468 3100
E-mail: [email protected]
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-redeye-life-science-day-301995674.html
SOURCE Medivir
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- October 2026 Global Sources Hong Kong Shows Phase I Opens Today
- STARMUS VIII Announces Two Young Changemakers as Junior Medal Winners
- Best Crypto To Buy Now: AlphaPepe Brings AI Trading to the PENGU and DOGE Meme Coin Showdown
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share